Previous close | 82.44 |
Open | 83.20 |
Bid | 82.09 x 400 |
Ask | 82.16 x 400 |
Day's range | 81.83 - 83.58 |
52-week range | 76.02 - 99.56 |
Volume | |
Avg. volume | 1,557,841 |
Market cap | 15.654B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 77.45 |
EPS (TTM) | 1.06 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 110.10 |
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'